Dacomitinib is an oral kinase inhibitor that can block the signaling pathway of tumor cells through its unique mechanism of action, inhibit tumor cell proliferation and growth, and achieve the effect of treating tumors.

1、 Drug name:

1. Product Name: VIZIMPRO

2. Common name: Dacomitinib

2、 Indications:

VIZIMPRO is a kinase inhibitor suitable for first-line treatment of metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21L858R substitution mutations, which need to be detected through FDA approved testing methods.

3、 Specifications and characteristics:

15mg and 45mg tablets

4、 Main components:

Active ingredient: Dacomitinib.

5、 Usage and dosage:

Recommended dosage: once daily, 45mg each time, orally, can be taken with or without food until disease progression or unacceptable toxicity occurs.

6、 Dose adjustment:

1. Depending on the severity of the adverse reactions, it may be necessary to reduce the dosage or suspend administration. Reduce to 30mg for the first time and to 15mg for the second time.

2. Dose adjustment for specific adverse reactions: such as permanent discontinuation of medication for interstitial lung disease (ILD); The dosage should be adjusted according to the severity of severe diarrhea, rash, etc.

7、 Medication precautions:

1. Before and after meals: can be taken with or without food.

2. Missed dose: If missed or vomited, do not take the next dose as planned.

3. Vomiting: Same as above, do not take supplements, continue to take the next dose as planned.

8、 Medication for special populations:

1. Pregnant and lactating women: May cause harm to the fetus, it is recommended that women use effective contraceptive measures during treatment and for at least 17 days after the last dose; Breastfeeding women should stop breastfeeding.

2. Children: The safety and effectiveness in children have not yet been determined.

3. Elderly individuals: Patients aged 65 and above may be more prone to serious adverse reactions and require close monitoring.

4. Patients with liver and kidney dysfunction: Mild to moderate liver and kidney dysfunction patients do not require dose adjustment; The recommended dosage for patients with severe liver and kidney dysfunction has not yet been determined.

9、 Adverse reactions:

1. Common adverse reactions (incidence>20%): diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, weight loss, hair loss, cough, itching, etc.

2. Serious adverse reactions: including interstitial lung disease (ILD), severe diarrhea, severe rash, etc.

10、 Contraindications:

There are no specific contraindications.

11、 Drug interactions:

1. Avoid co administration with proton pump inhibitors (PPIs) as it may lower the concentration of dacotinib; If antacids are needed, local acting antacids or H2 receptor antagonists can be chosen, but they must be administered at least 6 hours (before H2 receptor antagonist) or 10 hours (after H2 receptor antagonist) apart from the time of Dakatinib administration.

2. Avoid co administration with CYP2D6 substrates as Dakatinib may increase the concentration of these drugs, leading to serious or life-threatening toxicity.

12、 Storage method:

Stored in an environment of 20 ° C to 25 ° C (68 ° F to 77 ° F), the allowable temperature fluctuation range is 15 ° C to 30 ° C (59 ° F to 86 ° F).

Dacomitinibinformation